Eikon Therapeutics

Update in progress

EIKN (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Eikon Therapeutics, Inc. is a U.S. clinical biopharmaceutical company focused on medicines for serious unmet medical needs. Its programs include EIK1001, a systemically delivered TLR7/8 dual-agonist to stimulate innate and adaptive anti-tumor immunity; EIK1003 and EIK1004, selective PARP1 inhibitors for ovarian, breast, prostate and pancreatic cancers (EIK1004 is brain-penetrant for brain metastases and primary brain tumors); EIK1005, a WRN helicase inhibitor for MSI-H tumors; and EIK1006, a next-generation AR antagonist targeting resistant AR variants. Founded 2019, based in Millbrae, California.

Company score

Sentiment: 0.19; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.12; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive